Kirby Kevin Scott

Co-Founder Scott buys 86,207 ABL shares at $5.77; stock -48.4% from 52-week high, company unprofitable in last fiscal year despite 68.6% revenue growth

Kevin Scott, Co-Founder and President, purchased 86,207 shares at $5.77 on 2025-06-04, bringing total holdings to 12,447,415 shares. The purchase occurs as ABL trades -48.4% from its 52-week high of $11.73 and has declined -26.7% over the preceding 30 days. While the company reports strong revenue growth of 68.6% year-over-year with latest quarterly revenue of $44,139,346.00, it was unprofitable over its most recent full fiscal year, creating ambiguity about near-term earnings sustainability. A cluster of 2 additional insider purchases within 14 days of this transaction suggests coordinated confidence among management, though Scott's own cross-ticker track record of 100% well-timed sell timing at the 90-day mark indicates his historical trades have been opportunistic rather than conviction-driven.

Co-founder Scott sells 75,800 ABL shares at $8.00; stock down 37.4% from 52-wk high despite 48.5% revenue growth

Kirby Kevin Scott sold 75,800 shares at $8.00 on 2024-12-20 while retaining 12.36M shares post-transaction, a 0.6% reduction in his holding. The sale occurs with ABL trading at a 37.4% discount from its 52-week high of $12.47, yet the company posted annual revenue growth of 48.5% in its latest period. The disconnect between strong top-line expansion and depressed valuation—combined with a negative net income of $-5.1M—may explain the equity market discount. His cross-ticker track record shows 1 prior sell with an average 30-day return of -3.5%, and his prior ABL sale on 2024-11-21 also posted a -3.5% 30-day return, indicating a pattern of selling into weakness rather than at peaks.

Abacus Life Co-Founder Kevin Scott sells 156,250 shares ($1.2M) at $8.00; stock now $7.67, down 38.5% from 52-week high.

Kevin Scott sold 156,250 shares (156.2K shares) for $1,250,000.00 ($1.2M) at $8.00, reducing his holdings from 12,593,250 shares (12.59M shares) to 12,437,000 shares (12.44M shares). The transaction occurred on 2024-11-21 while the stock has declined significantly—down 38.5% from the 52-week high of $12.47 and down 15.1% over the past 30 days. Abacus Life reported negative net income of $-5,125,055.00 ($-5.1M) in the latest quarter despite strong annual revenue growth of +48.5%, suggesting operational pressures beneath topline expansion. This sale by a co-founder and president warrants examination in light of the company's profitability challenges and recent downward price momentum.